Latest other current assets for PHAS: $3.8M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2022), PHAS shows a other current assets of $3.8M. That compares with $5.6M in the prior-year period — down 33.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, PHAS's other current assets is now $3.8M (was $5.6M) — a 33.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.
Tracking PHAS's other current assets over time shows whether PhaseBio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $3.8M That compares with $5.6M in the prior-year period — down 33.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current assets page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $3.8M) with ownership activity and broader fundamentals.
PhaseBio Pharmaceuticals's other current assets is $3.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.